Tokyo, Japan

Hiroaki Tasaki

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2015-2019

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Hiroaki Tasaki: Innovator in Pharmaceutical Composition

Introduction

Hiroaki Tasaki, based in Tokyo, Japan, is a distinguished inventor known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of four patents, his work primarily focuses on developing stabilized pharmaceutical compositions.

Latest Patents

Among his latest innovative contributions are two notable patents. The first patent details a stabilized pharmaceutical composition comprising a specific compound, 5-{[(3R)-1-acryloylpyrrolidin-3-yl]oxy}-6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-pyrazine-2-carboxamide, also referred to as 'compound A'. This composition includes a pharmaceutical additive with a water activity value difference of 0.1 or more, contributing to its stabilization. The second patent presents a unique pharmaceutical composition that utilizes a complex between solifenacin, a pharmaceutically acceptable salt thereof, and an ion exchange resin, combined with an acrylic-based polymer.

Career Highlights

Hiroaki Tasaki has established a notable career at Astellas Pharma GmbH, where he continues to innovate and develop advanced pharmaceutical solutions. His expertise in pharmaceutical chemistry is complemented by his commitment to improving drug stability and efficacy for better patient outcomes.

Collaborations

Throughout his career, Hiroaki has collaborated with skilled professionals, including his coworkers Mitsuru Yoshida and Daisuke Tsunashima. These collaborations have played a vital role in enhancing the quality and scope of the pharmaceutical innovations he has brought to life.

Conclusion

Hiroaki Tasaki stands out as a prolific inventor in the pharmaceutical industry, with a focus on creating stabilized compositions that address critical medical needs. His ongoing work at Astellas Pharma GmbH continues to pave the way for future advancements in pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…